This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (9)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Osteoporosis  • Pain  • Adverse Effects  • Alert me on articles by topic

Bridget M. Kuehn

JAMA. 2006;295:2833-2836.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In 2003, case reports of a rare but serious condition occurring in patients taking bisphosphonates to prevent breakdown of bone began surfacing. Since then, reports of more than 2000 cases of this adverse event, osteonecrosis of the jaw, have spurred letters of caution from the manufacturer to physicians and dentists, revisions to the labels of some of the products, and recommendations from the US Food and Drug Administration (FDA).

Although most cases have occurred in patients receiving high-dose intravenous formulations of the drugs as part of cancer treatment, some have occurred in patients taking popular oral bisphosphonates to treat or prevent osteoporosis, suggesting that the problem may be a class effect. Scientists from the FDA have also recently identified another type of adverse event, severe bone, joint, or muscle pain associated with oral formulations.

Exposed bone in the mouth of a patient with osteonecrosis of the jaw. . . . [Full Text of this Article]

AN EMERGING PICTURE

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma
Kyle et al.
JCO 2007;25:2464-2472.
ABSTRACT | FULL TEXT  

Review of Postmenopausal Osteoporosis Pharmacotherapy
Mayes
Nutr Clin Pract 2007;22:276-285.
ABSTRACT | FULL TEXT  

Bone health and oral health
Kaye
Journal of the American Dental Association 2007;138:616-619.
ABSTRACT | FULL TEXT